- Overview
- Products
- Casting & Splinting
- Hand Hygiene
- Patient Monitoring
- Securement and Immobilization
- Skin & Wound Care
- Sterilization & Monitoring
- Surgical Solutions
- Vascular Access
- View All Products
- Conditions
- Adhesive Skin Damage
- Bloodstream Infections
- C. difficile Infection
- Incontinence-Associated Dermatitis
- Moisture Associated Skin Damage
- Oncology Care
- Securement
- Surgical Site Infections
- Venous Leg Ulcer/ Edema Management
- Wound Care and Management Solutions
- Resources
- Education
- Support
Help reduce the risk of bloodstream infections at all access points.
EXPLORE 3M SOLUTIONSIntravenous therapy is often the first critical intervention into a patient's body. While it is common, it is not without risk. Catheter-associated bloodstream infections (CABSIs) can be acquired at the time of the initial insertion or anytime throughout the duration of intravenous access — creating the potential for longer hospital stays¹⁻⁵, increased care costs²’⁷ and higher patient mortality⁶. Incorporating evidence-based standards to infusion therapy can help protect against the factors that may lead to increased risk of bloodstream infection.
-
60% of all CABSIs originate from some form of vascular access.⁵
-
1 in 4 patients who contract a CABSI will die.⁶
-
The cost to treat one CABSI averaged $45,000 USD per patient.³’⁷
Best practices for Infusion Therapy.
The Infusion Nurses Society (INS) is a global authority on infusion therapy, setting stringent standards for practice. Every five years, INS releases updated, peer-reviewed standards that reflect the latest evidence to define and develop best practices for all clinical settings. 3M can help you stay up to date so you can help deliver better patient outcomes.
We can help you meet current guidelines with evidence-based solutions.
Protecting patients from CABSIs requires a commitment from the care team to methodically adhere to evidence-based standards established by well-regarded organizations such as INS, SHEA, APIC and CDC.
3M partners with you, offering a portfolio of innovative solutions to help you protect every IV catheter site — from insertion to removal — every time. From hand hygiene and skin protectant to securement devices, disinfecting caps and more, our evidence-based products can help you deliver compassionate care, protect patients, help prevent the risks of costly complications, and improve patient satisfaction.
-
Antimicrobial IV Dressings
3M™ Tegaderm™ CHG I.V. Securement Dressings
3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing* is the only transparent dressing cleared by the FDA to reduce catheter-related bloodstream infections (CRBSI) and vascular catheter colonization, aligning with evidence-based guidelines and practice standards.
- Integrated IV dressing combines infection reduction with site visibility, catheter securement, and ease of use
- Provides immediate and continuous antimicrobial protection with integrated (CHG) gel pad
- Transparent film and gel pad allows continuous site visibility to easily assess for early signs of infection
- Helps keep catheters in place with large securement tape strip and conforming keyhole notch
*Important Safety Information for 3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing. Do not use 3M™ Tegaderm™ CHG I.V. Securement Dressing on premature infants or infants younger than two months of age. Use of this product on premature infants may result in hypersensitivity reactions or necrosis of the skin.The safety and effectiveness of 3M™ Tegaderm™ CHG I.V. Securement Dressing has not been established in children under 18 years of age. For full prescribing information, see the Instructions for Use (IFU). Rx only. -
Securement Dressings and Devices
3M™ Tegaderm™ I.V. Advanced Securement Dressings
3M™ Tegaderm™ I.V. Advanced Securement Dressings meet the 2021 Infusion Therapy Standards of Practice definition of an integrated securement device (IAD)⁵ and are designed to stabilize and secure vascular access securements (VADs).⁹
- Comfortable solution that provides patients with securement, site visibility and breathability all in one product
- Designed to maintain securement by preventing edge lift, flexing with patient movement and managing moisture
- A cost-effective IV and central line catheter securement solution
- Option for integrated antimicrobial protection with a chlorhexidine gluconate (CHG) dressing*
- Available with and without CHG*
3M™ Tegaderm™ I.V. Advanced Securement Dressings
3M™ PICC/CVC Securement Devices
Secure IVs quickly and effectively — without sutures. Designed to enhance patient comfort and mobility, they are an easy to apply/easy to remove securement system that can be worn for up to 7 days. Integrated CHG* gel pad provides immediate and continuous antimicrobial protection.
- Accommodates the majority of PICC and CVC catheters up to and including 12 French
- Eliminates the risks and costs of suture-related needlestick injuries
- Silicone adhesive holds securely, yet removes gently
- Available with and without CHG*; Integrated CHG* gel pad provides immediate and continuous antimicrobial protection.
3M™ PICC/CVC Securement Devices
*Important Safety Information for 3M™ Tegaderm™ CHG Chlorhexidine Gluconate I.V. Securement Dressing. Do not use 3M™ Tegaderm™ CHG I.V. Securement Dressing on premature infants or infants younger than two months of age. Use of this product on premature infants may result in hypersensitivity reactions or necrosis of the skin.The safety and effectiveness of 3M™ Tegaderm™ CHG I.V. Securement Dressing has not been established in children under 18 years of age. For full prescribing information, see the Instructions for Use (IFU). Rx only.8. Gorski, L. A., Hadaway, L., Hagle, M.E., Broadhurst, D., Clare, S., Kleidon, T., Meyer, B.M., Nickel, B., Rowley, S., Sharpe, E., Alexander, M. (2021). Journal of Infusion Nursing, 44(suppl 1):S1-S224. doi:10.1097/NAN.0000000000000396. Refer to the document to view verbatim, comprehensive standards and practice recommendations.
9. 3M data on file: EM-05-014359.
Port Protectors3M™ Curos™ Disinfecting Port Protectors
Curos™ Disinfecting Port Protectors* are alcohol-containing caps that twist onto IV access points for disinfection and protection. Consistent use of Curos disinfecting caps on IV needleless connectors is associated with decreased central line associated bloodstream infections (CLABSIs).¹⁰**
- Contain 70% isopropyl alcohol (IPA)
- Disinfect in 1 minute
- Protect the IV for up to 7 days if not removed
- Bright colored caps help caregivers verify that IV is protected at a glance
The 2021 Infusion Therapy Standards of Practice states that disinfecting caps containing 70% isopropyl alcohol were associated with lower rates of catheter-associated bloodstream infection (CABSI), while 70% isopropyl alcohol swabs were found to be least effective based on a meta-analysis of quasi-experimental studies.⁸
Use the entire family of 3M™ Curos™ Disinfecting Port Protectors to help reduce risks across all intraluminal access points.
3M™ Curos™ Disinfecting Port Protectors
* For full prescribing information, see the Instructions for Use (IFU). Rx only.** See Clinical Evidence Summary pages 9-14.
8. Gorski, L. A., Hadaway, L., Hagle, M.E., Broadhurst, D., Clare, S., Kleidon, T., Meyer, B.M., Nickel, B., Rowley, S., Sharpe, E., Alexander, M. (2021). Journal of Infusion Nursing, 44(suppl 1):S1-S224. doi:10.1097/NAN.0000000000000396. Refer to the document to view verbatim, comprehensive standards and practice recommendations.10. Voor in 't holt AF, Helder OK, Vos MC, et al. Antiseptic barrier cap effective in reducing central line-associated bloodstream infections: A systematic review and meta-analysis. Int J Nurs Stud. 2017; 69: 34-40.Hand Antiseptic3M™ Avagard™ Hand Antiseptic
Hands are the most common source of pathogen transmission. That’s why 3M developed a portfolio of hand hygiene solutions to help you protect your patients by reducing the risk of healthcare associated infections. For hand hygiene, the 2021 Infusion Therapy Standards of Practice currently recommends using soap and water, or as an alternative, using an alcohol-based hand rub that contains at least 60% alcohol or 70% isopropyl alcohol.⁸ 3M™ Avagard™ Hand Antiseptic meets those standards while providing additional benefits:
- Fast-acting microbe reduction
- Emollient rich formulation contains 61% w/w ethyl alcohol, maintains moisture for more comfortable and prolonged use¹¹
- Available with and without CHG*
- Gentle enough to promote repeated and frequent use**
*For Directions for Use, see product Drug Facts information.**FDA Drug Facts “recommended for repeated use” (NOTE: This statement is on the labeling for all configurations of Avagard: Avagard CHG, Avagard D and Avagard Foaming)8. Gorski, L. A., Hadaway, L., Hagle, M.E., Broadhurst, D., Clare, S., Kleidon, T., Meyer, B.M., Nickel, B., Rowley, S., Sharpe, E., Alexander, M. (2021). Journal of Infusion Nursing, 44(suppl 1):S1-S224. doi:10.1097/NAN.0000000000000396. Refer to the document to view verbatim, comprehensive standards and practice recommendations.11. 3M data on file. LIMS7780 and LIMS 8554.Skin Barrier3M™ Cavilon™ No Sting Barrier Film
A unique dual-polymer formulation that delivers exceptional durability and skin protection at vascular access sites. The 2021 Infusion Therapy Standards of practice currently recommends applying an alcohol-free skin barrier product compatible with the antiseptic solution. 3M™ Cavilon No Sting Barrier Film meets those standards. ⁸ ¹²⁻¹⁵
- Unique peel-down packaging that allows for aseptic delivery
- Compatible with chlorhexidine gluconate (CHG)¹⁶
- Alcohol-free and sting-free¹⁵
- Waterproof, breathable, fast drying
3M™ Cavilon™ No Sting Barrier Film
8. Gorski, L. A., Hadaway, L., Hagle, M.E., Broadhurst, D., Clare, S., Kleidon, T., Meyer, B.M., Nickel, B., Rowley, S., Sharpe, E., Alexander, M. (2021). Journal of Infusion Nursing, 44(suppl 1):S1-S224. doi:10.1097/NAN.0000000000000396. Refer to the document to view verbatim, comprehensive standards and practice recommendations.
12. George M, Ujwala P, Guduri, V, & Smith G. Use of a barrier film (3M™ Cavilon™ No Sting Barrier Film) to reduce local skin complications around peripherally inserted central catheter lines: A randomised prospective controlled study. WCET Journal. 2016; 8-13.
13. Pivkina AI, Gusarov VG, Blot SI, Zhivotneva IV, Pasko NV, Zamyatin MN. Effect of an acrylic terpolymer barrier film beneath transparent catheter dressings on skin integrity, risk of dressing disruption, catheter colonisation and infection. Intensive Crit Care Nurs. 2018; 46: 17-23.
14. Chen Y-H, Hsieh H-L, Shih W-M. Applying skin barrier film for skin tear management in patients with central venous catheterization. Adv Skin Wound Care. 2020; 33: 582-586.
15. Campbell K, Woodbury MG, Whittle H, Labate T, Hoskin A. A clinical evaluation of 3M™ Cavilon™ No Sting Barrier Film. Ostomy Wound Management.2000;46(1):24-30
16. 3M data on file. TEAM-MISC-05-005732 and SPONSOR FINAL RPT-05-002049.Skin and Nasal Antiseptic3M™ Skin and Nasal Antiseptic
(Povidone-Iodine Solution 5% w/w [0.5% available iodine] USP) Patient Preoperative Skin Preparation.Surgical site infections (SSIs) and bloodstream infections (BSIs) are common and costly. Staphylococcus aureus causes more health care associated infections (HAIs) than any other pathogen.¹⁷
3M™ Skin and Nasal Antiseptic can help reduce bacteria on the patient’s skin, a potential risk factor of SSIs and BSIs, and effectively provides broad spectrum antimicrobial activity in the nose*.
- Reduces nasal bacteria, including S. aureus by 99.5%, in one hour¹⁸*
- One-time application provides persistent antiseptic activity for at least 12 hours¹⁸
- Clinician application helps control compliance rather than a patient 5-day 2x/day dose¹⁹
- Safe for repetitive use (2x a day, 5 days on, 5 days off, for up to 3 months) ²⁰⁻²¹
*The clinical significance of in vitro data is unknown.17. Weiner LM, Webb AK, Limbago B, et al. Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol. 2016:37(11):1288-1301.
18. 3M Study-05-011100. 19. Phillips M, Rosenberg A, Shopsin B, et al. Preventing surgical site infections: A randomized, open-label trial of nasal mupirocin ointment and nasal povidone- iodinesolution. Infect Control Hosp Epidemiol. 2014;35 (7): 826-832. 21. Miller LG, McKinnell JA, Singh R, et al. Reduction of MDRO colonization in nursing home residents with routine use of chlorhexidine bathing and nasal iodophor (Project PROTECT). Presented at ID Week 2016, New Orleans, LA, October 2016. 22. 3M data on file 05-011210Comprehensive Infection Prevention
LEARN MORE ON INFECTION PREVENTION3M takes a holistic approach to help you identify and reduce infection and transmission risks, navigate rapidly changing standards and guidelines, and provide science-based solutions that can help you protect patients, staff and everyone who enters your facility.
3M resources to help you stay informed.
-
3M™ Health Care Academy offers free, quality educational content in a flexible online format. Choose from more than 50 CE credit courses to support your professional development.
-
Insights on skin, complications prevention and patient care.
-
The 3M™ Peak™ Clinical Outcomes Program provides you with the resources and partnership you need to define and achieve outcomes.
-
Resources to help you learn how to use the vascular access products that your facility uses.
CloseThank You
Thank you for connecting with 3M! We’ll be in touch with you shortly.
Our Apologies...
An error has occurred while submitting. Please try again later...
-
1. Maki D, Mermel L: Infections due to infusion therapy. In Hospital Infections, edn 4.Edited by Bennett JV, Brachman PS. Philadelphia: Lippincott-Raven; 1998:689–724.
2. CDC Vital Signs: Making health care safer: Reducing bloodstream infections. Centers for Disease Control and Prevention website. https://www.cdc.gov/vitalsigns/pdf/2011-03-vitalsigns.pdf Published March, 2011. Accessed June 18, 2017.
3. Blot SI, Depuydt P, Annemans L, Benoit D, Hoste E, De Waele JJ, Decruyenaere J, Vogelaers D, Colardyn F, Vandewoude KH. Clinical and economic outcomes in critically ill patients with nosocomial catheter-related bloodstream infections. Clin Infect Dis. 2005 Dec 1;41(11):1591-1598
4. Zimlichman E, Henderson D, et al. Health Care–Associated Infections: A Meta-analysis of Costs and Financial Impact on the US Health Care System. JAMA Intern Med. 2013 Dec 9-23;173(22):2039-2046. doi: 10.1001/ jamainternmed.2013.9763
